TRPV1 and diabetic neuropathy: Because there was no important difference in kcal/mol between 6-shogaol and the drug; therefore, it was noted that 6-shogaol could be developed as TRPV1 for the treatment of Painful Diabetic Neuropathy (PDN) (Fajrin et al., 2018; Fajrin et al., 2020b).